2020-01-28

NeoDynamics AB (publ) receives notification of granted patent on biopsy instrument in China

The expected announcement from the Chinese patent authority means that NeoDynamics´ unique biopsy device with front-loaded needle and integrated trocar, an important component of the NeoNavia® biopsy system is approved. The patent increases the protection of the NeoNavia biopsy system, which further strengthens the competitiveness.

“This notice, although expected, is positive for our shareholders as the Chinese market is a large and growing biopsy market and an important part of our global strategy. Together with our other patents, this is a confirmation of our unique technology and a good springboard for our upcoming work on applying for product approval in China. "We expect this to happen in the end of next year. The investment in the biopsy system means that we offer several different needle types with different functions, all with micropulse technology. This patent further enhances the protection of one of our needle types. The needle type allows the radiologist to take reliable, high quality tissue samples. The patented needle is already in use in our clinical studies in Europe. The biopsy system will be launched in the second quarter following the recent regulatory approval in the EU," says Anna Eriksrud, CEO of NeoDynamics.

For further information about NeoDynamics, please contact:                         

Anna Eriksrud, CEO NeoDynamics AB (publ), telephone: +46 8 522 79 667, e-mail: anna.eriksrud@neodynamics.com, or

Jörgen Vrenning, CFO/IR NeoDynamics AB (publ), Telephone: +46 708 519 648, email: jorgen.vrenning@neodynamics.com

 About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has an innovative biopsy system, NeoNavia®. The precision biopsy system is built on a patented micro-pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia® is evaluated at leading clinics in UK, Germany and Sweden. A commercial launch is expected in 2020.

www.neodynamics.com

About NeoNavia

NeoNavia is the brand name for the entire biopsy system intended to be used under ultrasound guidance.  NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by the micro-pulses enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About the micro-pulse technology

The patented micro-pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type. The pneumatic driver that generates micro-pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.